Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.

By B. Fellström, A. Jardine, R. Schmieder, H. Holdaas, K. Bannister, J. Beutler, D. Chae, A. Chevaile, S. Cobbe, C. Grönhagen‐Riska and 18 more. New England Journal of Medicine, 2009

1,981 citations recorded by the source corpus.

Subfields: Cancer Research, Cardiology and Cardiovascular Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/00087b69ac5dcc63978a7a95db41b01fad37c3f7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Cardiology and Cardiovascular Medicine

In Surgery

Citations in the corpus

Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) (2022, background): “An exception may be patients with kidney failure treated with dialysis for whom primary prevention of ASCVD events with a statin has been generally ineffective.(47,49,50) High-intensity statin is recommended for secondary prevention for all patients with known ASCVD.”
Reprint: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. (2014, background): “In the 4 RCTs reviewed that specifically addressed statin treatment in these groups, there were individuals with and without heart disease (86-89).”
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014, background): “In the 4 RCTs reviewed that specifically addressed statin treatment in these groups, there were individuals with and without heart disease (86-89).”
Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. (2013, background): “The one exception may be in patients with renal failure, as statins have failed to show efficacy consistently is in diabetic patients undergoing haemodialysis.(122,123) Moreover, high-dose more potent”
Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). (2011, background): “placebo in hemodialysis patients did not demonstrate benefit.(54,55) More recently, in the SHARP trial, the combina-”
A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association (2023, background): “191,192 However, in a post hoc analysis of patients with diabetes on dialysis, rosuvastatin use was associated with lower risk of adverse cardiovascular outcomes.”
European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) (2012, positive): “Statin therapy has a beneficial effect on CVD outcomes in CKD stages 2 and 3 and slows the rate of kidney function loss.(493) 4.”